Search results for "survival analysi"

showing 10 items of 752 documents

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers

2013

The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear. Here, we report on a retrospective study of 47 patients with either newly diagnosed (30 patients) or recurrent (17 patients) glioblastoma (WHO grade IV) treated with BCNU (bis-chloroethylnitrosourea) wafers. Thirteen of the newly diagnosed patients received local BCNU and irradiation only (first-line BCNU), while 17 patients additionally received concomitant and adjuvant temozolomide (TMZ) radiochemotherapy (first-line BCNU + TMZ). Of the 17 patients treated for recurrent glioblastoma (second-line BCNU), 16 had rec…

AdultMaleOncologymedicine.medical_specialtyMethyltransferaseDacarbazineDisease-Free SurvivalO(6)-Methylguanine-DNA Methyltransferase03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsTemozolomidemedicineHumansKarnofsky Performance StatusPromoter Regions GeneticAntineoplastic Agents AlkylatingSurvival analysisAgedRetrospective StudiesCarmustineTemozolomideBrain Neoplasmsbusiness.industryO-6-methylguanine-DNA methyltransferaseChemoradiotherapyGeneral MedicineDNA MethylationMiddle AgedPrognosisCarmustineCombined Modality TherapySurvival Analysis3. Good healthSurgeryDacarbazine030220 oncology & carcinogenesisConcomitantFemaleSurgeryNeurology (clinical)Glioblastomabusiness030217 neurology & neurosurgeryChemoradiotherapymedicine.drugBritish Journal of Neurosurgery
researchProduct

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

2016

Abstract Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for …

AdultMaleOncologymedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmenteducationDiseaseRelapse preventionChimerismYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceGermanyInternal medicineSecondary PreventionHumansTransplantation HomologousMedicineddc:610ChildChildhood Acute Lymphoblastic LeukemiaImmunosuppression TherapyTransplantationbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisMinimal residual diseaseSurgeryTransplantationChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisCohortFemaleImmunotherapybusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

2014

More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age.In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008. We used data from the 30 cancer registries (across 20 countries) that provided continuous incidence and …

AdultMalePathologymedicine.medical_specialtyAdolescentPopulationRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalNOCohort StudiesYoung AdultCause of DeathConfidence IntervalsHematologic Neoplasms/diagnosis/mortality/therapyMedicineHumansRegistrieseducationSurvival analysisddc:613Cause of deathAgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryIncidence (epidemiology)Absolute risk reductionRetrospective cohort studyMiddle AgedCombined Modality TherapySurvival AnalysisEuropeOncologyHematologic NeoplasmsFemalebusinessDemographyCohort studyThe Lancet. Oncology
researchProduct

CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

2007

A role for CXCR3, the receptor for chemokines Mig, IP-10 and interferon-inducible T cell alpha-chemoattractant, in tumour cell migration during melanoma progression has been proposed.To analyse CXCR3 expression in primary cutaneous malignant melanomas and its comparison with clinicopathological and prognostic factors.A retrospective immunohistochemical study was carried out on formalin-fixed paraffin-wax-embedded sections from 82 patients with primary invasive cutaneous melanomas, with a monoclonal antibody to CXCR3 (clone 49801.111; RD Systems). Immunoreactivity was semiquantitatively evaluated: labelling intensity (0, absent; 1, weak; 2, moderate; 3, strong) multiplied by the percentage o…

AdultMalePathologymedicine.medical_specialtyReceptors CXCR3Skin NeoplasmsCXCR3Pathology and Forensic MedicineImmunoenzyme TechniquesmedicineBiomarkers TumorHumansNeoplasm InvasivenessLymph nodeMelanomaAgedRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryMelanomaGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival AnalysisNeoplasm Proteinsmedicine.anatomical_structureLymphatic MetastasisCutaneous melanomaDisease ProgressionImmunohistochemistryFemaleReceptors ChemokineOriginal ArticleSkin cancerbusinessImmunostainingJournal of clinical pathology
researchProduct

Strategy for Long-Term Surveillance at the German Childhood Cancer Registry - an Update

2011

Background The objective of this paper is to provide information about the quality (e.g. completeness, response) of long-term surveillance in German paediatric oncology and haematology based on the structures implemented by the German Childhood Cancer Registry (GCCR). Methods The GCCR contacts parents or patients to collect and update information on a minimal set of follow-up health status data (e.g. late relapses, subsequent neoplasms, current address) and exchanges this information regularly with the appropriate clinical trials. Results Between 2006 and 2010, GCCR approached a total of about 20,000 patients (contact at the age of 16 years, inquiry concerning the health status) in the cont…

AdultMalePediatricsmedicine.medical_specialtyAdolescentDatabases FactualLymphomaCross-sectional studyHealth StatusMEDLINECentral Nervous System NeoplasmsCohort StudiesGermanYoung AdultCause of DeathGermanyNeoplasmsHumansMedicineRegistriesSurvivorsYoung adultChildClinical Trials as TopicChildhood Cancer RegistryLeukemiabusiness.industryMiddle AgedLong-Term CareSurvival Analysislanguage.human_languageClinical trialLong-term careCross-Sectional StudiesChild PreschoolPopulation SurveillanceFamily medicinePediatrics Perinatology and Child HealthQuality of LifelanguageFemalebusinessCohort studyKlinische Pädiatrie
researchProduct

Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States

2014

BackgroundAdulthood acute lymphoblastic leukemia (ALL) is a rare disease. In contrast to childhood ALL, survival for adults with ALL is poor. Recently, new protocols, including use of pediatric protocols in young adults, have improved survival in clinical trials. Here, we examine population level survival in Germany and the United States (US) to gain insight into the extent to which changes in clinical trials have translated into better survival on the population level.MethodsData were extracted from the Surveillance, Epidemiology, and End Results database in the US and 11 cancer registries in Germany. Patients age 15-69 diagnosed with ALL were included. Period analysis was used to estimate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentNon-Clinical MedicineEpidemiologyScienceLymphoblastic LeukemiaBiostatisticsHematologic Cancers and Related DisordersGermanyLeukemiasEpidemiologyHumansMedicineStatistical MethodsYoung adultSurvival analysisAgedHealth Care PolicyMultidisciplinaryRelative survivalbusiness.industryStatisticsQRCancers and NeoplasmsCancerHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute Lymphoblastic Leukemiamedicine.diseaseSurvival AnalysisUnited StatesClinical trialOncologyUnited States ; age groups ; cancer treatment ; German people ; Germany ; cancer detection and diagnosis ; acute lymphoblastic leukemia ; leukemiasMedicineFemaleHealth StatisticsbusinessMathematicsResearch ArticleRare diseasePLoS ONE
researchProduct

AML transformation in 56 patients with Ph- MPD in two well defined populations.

2009

The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (MPD) have an inherent tendency for transformation into acute myelogenous leukaemia (AML). The long-term rate of leukaemic transformation in unselected MPD patients was studied in well-defined MPD populations in Gothenburg, Sweden and the Cote d'Or area, Burgundy, France, respectively. Over a median observation time of 15 yr, 56 subjects (7%) out of a total of 795 patients with Ph- MPD transformed to AML. The yearly incidence of AML transformation was 0.38% in polycythaemia vera (PV), 0.37% in essential thrombocythaemia (ET) and 1.09% in idiopathic myelofibrosis (IMF). The incidence of AML development was signif…

AdultMalePediatricsmedicine.medical_specialtyPolycythaemiaMyeloidIdiopathic myelofibrosisGastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL Negativehemic and lymphatic diseasesInternal medicineMedicineHumansSurvival analysisAgedAged 80 and overMyeloproliferative Disordersbusiness.industryIncidence (epidemiology)HematologyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisChronic myeloproliferative disordersLeukemiamedicine.anatomical_structureFemalebusinessMale predominanceEuropean journal of haematology
researchProduct

Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outco…

2005

AbstractPurpose: Human leukocyte antigen (HLA) class I antigen defects, which are frequently present in head and neck squamous cell carcinoma (HNSCC) cells may provide the tumor with an escape mechanism from immune surveillance. Scanty information is available about mechanisms underlying HLA class I antigen defects in both lesions and cell lines from HNSCC. In this study, we investigate the role of antigen processing machinery (APM) component abnormalities in the generation of deficient HLA class I surface expression of HNSCC cells.Experimental Design: Using immunohistochemistry, Western blot, and RT-PCR analyses we correlated the expression of the IFN-γ inducible proteasome subunits and of…

AdultMaleProteasome Endopeptidase ComplexCancer ResearchPathologymedicine.medical_specialtyBlotting WesternDown-RegulationHuman leukocyte antigenBiologyCell LineInterferon-gammaATP Binding Cassette Transporter Subfamily B Member 3HLA AntigensMultienzyme ComplexesCell Line TumorTumor Cells Culturedotorhinolaryngologic diseasesmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 2AgedReverse Transcriptase Polymerase Chain ReactionAntigen processingHistocompatibility Antigens Class ICancerMiddle Agedmedicine.diseaseImmunohistochemistrySurvival AnalysisHead and neck squamous-cell carcinomaGene Expression Regulation NeoplasticCysteine Endopeptidasesstomatognathic diseasesOncologyHead and Neck NeoplasmsCarcinoma Squamous Cellbiology.proteinImmunohistochemistryTAP2ATP-Binding Cassette TransportersFemaleTAP1Clinical Cancer Research
researchProduct

Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factors

2014

Suicide is a major cause of premature death in psychosis. Earlier stages have been associated with higher risk. However, such risk periods have not been specifically determined and risk factors for suicidal behaviour may change over those periods, which may have crucial implications for suicide prevention. The aim of this study was to determine and characterize the highest risk period for suicide in a representative sample of first-episode psychosis (FEP) patients. Suicidal behaviour prior to first presentation of psychosis and during a 3-year follow-up was examined in a sample of 397 individuals. Risk factors for suicidal behaviour during specific time periods were investigated and compare…

AdultMalePsychosismedicine.medical_specialtyAdolescentSpecific riskPoison controlNeuropsychological TestsSuicide preventionYoung AdultCognitionmedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryPsychiatric Status Rating ScalesPharmacologyFirst episodeSuicide attemptMiddle Agedmedicine.diseaseSurvival AnalysisSuicidePsychiatry and Mental healthPsychotic DisordersNeurologySchizophreniaRegression AnalysisAnxietyFemaleNeurology (clinical)medicine.symptomPsychologySelf-Injurious BehaviorClinical psychologyEuropean Neuropsychopharmacology
researchProduct